161 related articles for article (PubMed ID: 10699539)
1. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies.
Kornblau S; Benson AB; Catalano R; Champlin RE; Engelking C; Field M; Ippoliti C; Lazarus HM; Mitchell E; Rubin J; Stiff PJ; Vokes E; Wadler S
J Pain Symptom Manage; 2000 Feb; 19(2):118-29. PubMed ID: 10699539
[TBL] [Abstract][Full Text] [Related]
2. Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease.
Pai V; Porter K; Ranalli M
Pediatr Blood Cancer; 2011 Jan; 56(1):45-9. PubMed ID: 21108438
[TBL] [Abstract][Full Text] [Related]
3. [Management of chemotherapy induced diarrhea].
Schultz M; Schölmerich J; Kullmann F
Z Gastroenterol; 2004 Jun; 42(6):527-38. PubMed ID: 15190449
[TBL] [Abstract][Full Text] [Related]
4. Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Wadler S; Benson AB; Engelking C; Catalano R; Field M; Kornblau SM; Mitchell E; Rubin J; Trotta P; Vokes E
J Clin Oncol; 1998 Sep; 16(9):3169-78. PubMed ID: 9738589
[TBL] [Abstract][Full Text] [Related]
5. Octreotide in the management of treatment-related diarrhoea.
Baillie-Johnson HR
Anticancer Drugs; 1996 Jan; 7 Suppl 1():11-5. PubMed ID: 8822080
[TBL] [Abstract][Full Text] [Related]
6. Octreotide in the management of diarrhea induced by graft versus host disease.
Ippoliti C; Neumann J
Oncol Nurs Forum; 1998 Jun; 25(5):873-8. PubMed ID: 9644703
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy induced diarrhea.
Richardson G; Dobish R
J Oncol Pharm Pract; 2007 Dec; 13(4):181-98. PubMed ID: 18045778
[TBL] [Abstract][Full Text] [Related]
8. The assessment and management of cancer treatment-related diarrhea.
O'Brien BE; Kaklamani VG; Benson AB
Clin Colorectal Cancer; 2005 Mar; 4(6):375-81; discussion 382-3. PubMed ID: 15807929
[TBL] [Abstract][Full Text] [Related]
9. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies.
Ippoliti C; Champlin R; Bugazia N; Przepiorka D; Neumann J; Giralt S; Khouri I; Gajewski J
J Clin Oncol; 1997 Nov; 15(11):3350-4. PubMed ID: 9363865
[TBL] [Abstract][Full Text] [Related]
10. Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients.
Ippoliti C
Am J Health Syst Pharm; 1998 Aug; 55(15):1573-80. PubMed ID: 9706182
[TBL] [Abstract][Full Text] [Related]
11. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation.
Bianco JA; Higano C; Singer J; Appelbaum FR; McDonald GB
Transplantation; 1990 Jun; 49(6):1194-5. PubMed ID: 2360261
[No Abstract] [Full Text] [Related]
12. [Management of cancer treatment-related diarrhea and constipation].
Tsuji Y; Sagawa T; Takayanagi N; Hirayama Y; Sakamaki S
Nihon Rinsho; 2003 Jun; 61(6):966-72. PubMed ID: 12806944
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation.
Morton AJ; Durrant ST
Clin Transplant; 1995 Jun; 9(3 Pt 1):205-8. PubMed ID: 7549062
[TBL] [Abstract][Full Text] [Related]
14. Continuous octreotide infusion for the treatment of secretory diarrhea caused by acute intestinal graft-versus-host disease in a child.
Beckman RA; Siden R; Yanik GA; Levine JE
J Pediatr Hematol Oncol; 2000; 22(4):344-50. PubMed ID: 10959906
[TBL] [Abstract][Full Text] [Related]
15. Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease.
Ely P; Dunitz J; Rogosheske J; Weisdorf D
Am J Med; 1991 Jun; 90(6):707-10. PubMed ID: 2042686
[TBL] [Abstract][Full Text] [Related]
16. Recommended guidelines for the treatment of cancer treatment-induced diarrhea.
Benson AB; Ajani JA; Catalano RB; Engelking C; Kornblau SM; Martenson JA; McCallum R; Mitchell EP; O'Dorisio TM; Vokes EE; Wadler S
J Clin Oncol; 2004 Jul; 22(14):2918-26. PubMed ID: 15254061
[TBL] [Abstract][Full Text] [Related]
17. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
Rosenoff S
Support Care Cancer; 2004 Aug; 12(8):561-70. PubMed ID: 15160318
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy-induced diarrhea].
Kobayashi K
Gan To Kagaku Ryoho; 2003 Jun; 30(6):765-71. PubMed ID: 12852342
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
Rosenoff SH; Gabrail NY; Conklin R; Hohneker JA; Berg WJ; Warsi G; Maloney J; Benedetto JJ; Miles EA; Zhu W; Anthony L
J Support Oncol; 2006 Jun; 4(6):289-94. PubMed ID: 16805331
[TBL] [Abstract][Full Text] [Related]
20. Constipation and diarrhea in patients with cancer.
Solomon R; Cherny NI
Cancer J; 2006; 12(5):355-64. PubMed ID: 17034672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
